GSK to produce 60 million Novavax doses for Britain

New computational models to understand colon cancer
29 March 2021
New technique provides detailed map of lung pathology in COVID-19
29 March 2021

GSK to produce 60 million Novavax doses for Britain

GlaxoSmithKline is to manufacture 60 million doses of the COVID-19 vaccine developed by US biotech company Novavax for UK distribution, the British pharmaceutical giant said in a statement Monday.

Comments are closed.